Long-term outcomes and predictive factors for survival in premenopausal breast cancer treated with tamoxifen

Conditions

Premenopausal patients with invasive breast cancer Cancer Malignant neoplasm of breast

Lundgren C, Tutzauer J, Church SE, Stål O, Ekholm M, Forsare C, Nordenskjöld B, Fernö M, Bendahl PO, Rydén L.

2023-09-295 citations

10.1186/s13058-023-01719-z

PAM50 subtyping and ROR score add long-term prognostic information in premenopausal breast cancer patients.

Lundgren C, Bendahl PO, Church SE, Ekholm M, Fernö M, Forsare C, Krüger U, Nordenskjöld B, Stål O, Rydén L.

2022-05-0911 citations

10.1038/s41523-022-00423-z

Tumour-infiltrating lymphocytes as a prognostic and tamoxifen predictive marker in premenopausal breast cancer: data from a randomised trial with long-term follow-up.

Lundgren C, Bendahl PO, Ekholm M, Fernö M, Forsare C, Krüger U, Nordenskjöld B, Stål O, Rydén L.

2020-12-2333 citations

10.1186/s13058-020-01364-w

Interventions

The SBII:2 BioLong study is based on a prospective multicenter randomized clinical trial with > 30 years of follow-up of adjuvant tamoxifen We will collect formalin-fixed archival tissue for gross ev

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Patients radically operated for invasive breast cancer stage II in the SBII:2 trial

Exclusion criteria

Exclusion criteria: 1. Postmenopausal status 2. Metastatic disease

Design outcomes

Primary

Measure	Time frame
BCFi (Breast cancer free interval) over the ~30-year period, measured using patient notes	—

Secondary

Measure	Time frame
1. D-RFi (Distant Recurrence Free interval) over the ~30-year period, measured using patient notes 2. Breast cancer mortality over the ~30-year period, measured using patient notes 3. Overall mortality over the ~30-year period, measured using patient notes	—

Countries

Sweden

Outcome results

None listed